Schering-Plough

Bryan Hanson Named CEO of 3M's Health Care Business Group

Retrieved on: 
Tuesday, August 22, 2023
Minimally invasive procedure, Walgreens Boots Alliance, Massachusetts College of Liberal Arts, Medical device, Senior, Pharmacia, Surgery, Information technology, Zimmer Biomet, Culture, Schering-Plough, Women's Health Care Nurse Practitioner-Board Certified, Roman, Pharmacia & Upjohn, Bristol Myers Squibb, Sale, Cox, Cardinal Health, Patient, Health care, Texas Instruments, Outline of health sciences, Seattle Mariners, Growth, Medtech, NYSE, Management, Pharmaceutical industry, Nursing, AmeriCares, Medtronic, Novartis, Covidien

Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.

Key Points: 
  • Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.
  • 3M's Health Care Business Group, with $8.4 billion in sales in 2022, is a diversified health care technology leader with a deep and diverse portfolio of trusted brands, global capabilities, and leadership in attractive end market segments such as wound care, oral care, health care IT, and biopharma filtration.
  • As a standalone business, Health Care will be well-positioned to deliver industry-leading innovation that enables better, smarter, and safer health care for patients worldwide.
  • "I am honored and excited to join 3M's Health Care Business Group at such an important time in its evolution," said Hanson.

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, August 17, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, SAB, Pancreatic cancer, University of Texas Southwestern Medical Center, PPD, IQVIA, University, Senior, Gastrointestinal cancer, TAMP, Evotec, Schering-Plough, Neoplasm, ESMO, New Drug Application, Survival, NDA, Coronavirus Scientific Advisory Board, ASX, Immunotherapy, IMU, MD, Patient, Research, FDA, D, Pharmaceutical industry, Cryptocurrency

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023.
  • Second Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents as of June 30, 2023, were $6.0 million.
  • G&A Expenses: General and administrative expenses were $1.4 million for the second quarter ended June 30, 2023, compared to $1.2 million for the quarter ended June 30, 2022.
  • Net Loss: Net loss was $2.3 million for the quarter ended June 30, 2023, compared to net loss of $2.6 million for the quarter ended June 30, 2022.

ARCH Venture Partners Announces Appointment of Kent Rogers as Venture Partner

Retrieved on: 
Friday, July 14, 2023
Emory University, Schering-Plough, ARCH Venture Partners, Business, MBA, Kent, Acorda Therapeutics, Science, Açorda, ARCH, Business administration, PBM, Health, Therapy, Pharmaceutical industry, Indiana University, UnitedHealth Group, Merck

CHICAGO, July 14, 2023 /PRNewswire/ -- ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Kent Rogers as Venture Partner.

Key Points: 
  • CHICAGO, July 14, 2023 /PRNewswire/ -- ARCH Venture Partners, one of the world's leading early-stage technology venture firms, today announced the appointment of life sciences industry veteran Kent Rogers as Venture Partner.
  • "Kent brings a long history of creating commercialization strategies to assist ARCH portfolio companies, and we are extremely pleased to have him join the team," said ARCH Managing Director Paul Berns.
  • "ARCH is committed to building innovative companies that impact and improve human health.
  • "I feel privileged to be joining ARCH Venture Partners and look forward to working with proven industry veterans who have successfully driven disruptive innovation through sound investment strategies that back great science and partner with talented leadership to bring cutting-edge discoveries to market," said Rogers.

Hill+Knowlton Appoints Craig Buchholz US CEO

Retrieved on: 
Tuesday, July 11, 2023
Consulting, Communications, Professional Services, Public Relations, Investor Relations, Vaccine, Annamaria, Temple University, Schering-Plough, Arthur, Policy, Hill+Knowlton Strategies, WPP, Multimedia, Aspen, Acquisition, Procter & Gamble, GM, Growth, Merck, Johnson & Johnson, Aspen Institute, P&G, General Motors, Management, Film industry, Pharmacia, Pfizer

Hill+Knowlton Strategies, one of the world’s leading strategic communications companies, today announced the appointment of Craig Buchholz, former head of communications for General Motors, as its new US CEO effective July 12th.

Key Points: 
  • Hill+Knowlton Strategies, one of the world’s leading strategic communications companies, today announced the appointment of Craig Buchholz, former head of communications for General Motors, as its new US CEO effective July 12th.
  • Prior to GM, Buchholz was Chief Communications Officer for Procter & Gamble, where he served as a key advisor to the CEO and other C-suite leaders.
  • “I am proud and delighted to welcome Craig Buchholz as the new leader of our US business,” said DeSalva.
  • “I could not be more enthusiastic about stepping into this CEO role at an important inflection point for Hill+Knowlton,” said Buchholz.

Cytovation appoints Olav Hellebø to its Board of Directors

Retrieved on: 
Wednesday, July 5, 2023
IESE Business School, Schering-Plough, Biotechnology, Clavis, Bachelor of Business Administration, MBA, ReNeuron, Business administration, Novartis, Hofstra University, Prostate cancer, Pharmaceutical industry

Bergen, Norway, July 5th, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.

Key Points: 
  • Bergen, Norway, July 5th, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.
  • Mr. Hellebø brings extensive international leadership experience, both in the US and Europe, across major pharmaceutical and biotechnology companies.
  • Olav currently serves on the Board of Antev, a UK-based private biotechnology company with a focus on prostate cancer.
  • Stein Christian Mohn, Chairman at Cytovation said: “We are very pleased to welcome Olav to our Board of Directors.

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines

Retrieved on: 
Wednesday, June 28, 2023
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Beth Israel Deaconess Medical Center, SAB, Idera, Inc., Partnership, Central nervous system, University, University of Massachusetts, Therapy, Oxford, Schering-Plough, Therapeutic index, Oligonucleotide, ATX, RNA, IP, Antibody, Doctor of Philosophy, CNS, TCR, UCB, Patient, Peptide, Medicine, Biology, Liver, Merck, Ecosystem, Rare, Immunology, TLR, Alloy, Gene, Fine chemical, Vaccine, Pharmaceutical industry, Chemistry

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.

Key Points: 
  • Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
  • Alloy has exclusively licensed IP underlying the AntiClastic ASO platform from Sudhir Agrawal’s Arnay Sciences LLC.
  • “The AntiClastic format has the potential to transform the development of antisense therapeutics,” said Agrawal.
  • In launching the AntiClastic ASO platform, Alloy is expanding into its third biologic modality, genetic medicines.

Health Monitor Network® Welcomes Industry Veteran Kelli Vincent-Rodriguez to Build Partnerships with Over-the-Counter and Consumer Brands

Retrieved on: 
Tuesday, June 27, 2023
Healthcare Businesswomen's Association, Senior, Marketing, Schering-Plough, CPG, Woman, Harvard University, HCP, Siena College, Patient, Physician, OTC, George Washington University, Female, Management, Pharmaceutical industry, Merck

MONTVALE, N.J., June 27, 2023 /PRNewswire/ -- Pioneering healthcare communications company Health Monitor Network today announced the hiring of Kelli Vincent-Rodriguez as Senior Vice President for Over-the-Counter/Consumer Packaged Goods (OTC/CPG) clients. In this new leadership role, Kelli will report to Augie Caruso, Executive Vice President of Sales & Key Accounts, to position Health Monitor Network as a trusted partner to OTC/CPG brands as they strengthen their relationships with providers and patients.

Key Points: 
  • "There is a tremendous opportunity for OTC brands to build trusted relationships with patients and their healthcare providers through content.
  • Health Monitor Network is poised to facilitate these relationships," explained Kelli.
  • "I'm excited to bring my experience in consumer markets and pharmaceuticals together to help OTC brands build awareness and loyalty at the point of care."
  • "We've seen strong demand from OTC/CPG brands as they build true omnichannel marketing campaigns to better engage with healthcare practitioners," said David Paragamian, CEO at Health Monitor Network.

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Retrieved on: 
Thursday, June 22, 2023
Odyssey, Partnership, Drug development, Doctor of Philosophy, Stanford University, Crizotinib, ACRV, Schering-Plough, Mirati Therapeutics, Neoplasm, Breast, Medicine, AP3, Research, Bangladesh Technical Education Board, Lung, Development, Patient, Patent, Washington University School of Medicine, Growth, American Cancer Society, Axitinib, Phase, Therapy, Pharmaceutical industry, Pfizer, Mirati

“We are thrilled about Chuck’s appointment and look forward to his contributions to the board,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “We are thrilled about Chuck’s appointment and look forward to his contributions to the board,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • “Chuck is a highly accomplished leader in our industry who has excelled as both a business executive as well as a precision oncology drug developer.
  • He founded Mirati Therapeutics where he built a world class oncology team resulting in the approval of its best-in-class KRASG12C inhibitor.
  • Dr. Baum serves on the board of directors at PMV Pharmaceuticals, Inc., Odyssey Therapeutics and Poseida Therapeutics.

RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, SAB, Pancreatic cancer, Interim, University, Pancreatic Cancer Action Network, Hematology, Schering-Plough, Cancer, Jim Valvano, UCSF Helen Diller Family Comprehensive Cancer Center, Lustgarten Foundation for Pancreatic Cancer Research, NIH Intramural Research Program, ASCO, EORTC, UCSF, Patient, Division, United States Air Force Scientific Advisory Board, Research, NCI, Armendariz v. Foundation Health Psychcare Services, Inc., Pharmaceutical industry, Medicine

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).
  • She also serves as Chair of the NCCN Guidelines Panel on Pancreatic Cancer (since 2000), editor-in-chief of JNCCN, and on the ASCO Conquer Cancer Foundation Board.
  • Previously, Dr. Tempero has served on the ASCO Board of Directors, as ASCO President, and as a member of FDA’s Oncology Drug Advisory Committee.
  • She co-directed the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia.

TraceLink Announces Appointment of George Llado, former Merck and Alexion CIO, to Board of Directors

Retrieved on: 
Thursday, May 18, 2023
National Center for Telecommunications Technologies, Lladó, Senior, Information technology, Temple University, Schering-Plough, Health care, Sierra Ventures, National Center for Women & Information Technology, Supplier performance management, Merck & Co., Alexion Pharmaceuticals, Patient, Supply chain, Alexion, CIO, Growth, Commercial, Rare, Temple University Hospital, Woman, Safety, Fine chemical, Cryptocurrency, Pharmaceutical industry, Management, Pharma, Merck

BOSTON, May 18, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced the appointment of George Llado to the TraceLink Board of Directors.

Key Points: 
  • BOSTON, May 18, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced the appointment of George Llado to the TraceLink Board of Directors.
  • "After spending more than a decade as a customer that depended on TraceLink's mission critical traceability and serialization solutions," said Llado, "I am delighted to join TraceLink's Board of Directors.
  • In addition to this appointment, he serves on the Board of Charles River Laboratories and The National Center for Women & Information Technology.
  • "George has been an esteemed customer and partner of TraceLink from day one," said Shabbir Dahod, President and CEO at TraceLink.